<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04847622</url>
  </required_header>
  <id_info>
    <org_study_id>NEAT ID 909REM</org_study_id>
    <nct_id>NCT04847622</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.</brief_title>
  <acronym>909REM</acronym>
  <official_title>A Multi-centre, Multi-country Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults With Covid-19 Who Have Been Treated With Remdesivir.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NEAT ID Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NEAT ID Foundation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-centre, multi-country retrospective cohort study. At least 450COVID-19 cases&#xD;
      from up to 20 participating study sites who meet all eligibility criteria will be included in&#xD;
      the analysis. Deidentified data will be extracted from electronic medical record (EMR)&#xD;
      databases, clinical registries, case series or additional sources from participating sites&#xD;
      and countries, and then entered into a structured e-CRF system. addition, each site/country&#xD;
      will be surveyed to determine the local standard of care therapy for COVID-19 infection and&#xD;
      to determine if standard protocols were/are in place for the use of Remdesivir and if/how the&#xD;
      protocols changed over time.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Day 28</time_frame>
    <description>All-cause mortality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical status assessed by a 7-point ordinal scale</measure>
    <time_frame>Day 14</time_frame>
    <description>7-point ordinary scale:&#xD;
Death&#xD;
Hospitalised, on invasive mechanical ventilation or ECMO&#xD;
Hospitalised, on non-invasive ventilation or high flow oxygen devices&#xD;
Hospitalised, requiring low flow supplemental oxygen&#xD;
Hospitalised, not requiring supplemental oxygen -requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalised, not requiring supplemental oxygen -no longer requires ongoing medical care&#xD;
Not hospitalised</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of clinical improvement.</measure>
    <time_frame>Day 14</time_frame>
    <description>Proportion of clinical improvement at Day 14, defined as a â‰¥ 2-point improvement from Day 1 on a 7-point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of disease</measure>
    <time_frame>Day 28</time_frame>
    <description>Severity of disease on Day 7, Day 14 and Day 28 based on NEWS 2 score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status assessed by a 7-point ordinal scale</measure>
    <time_frame>Day 28</time_frame>
    <description>Clinical status assessed by a 7-point ordinal scale on Day 28 (or at last observation if discharged or died prior to this time point) in those still Hospitalised after day 14.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to SpO2</measure>
    <time_frame>Day 28</time_frame>
    <description>Time to SpO2 &gt; 94% on room air (number of days when evaluation made on day 7, 14 or 28)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of oxygen therapy</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Duration of oxygen therapy (total days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Admission to the Intensive Care Unit</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Admission of a subject to the Intensive Care Unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time on mechanical ventilation/ECMO</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Need for and time on mechanical ventilation/ECMO of hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalisation</measure>
    <time_frame>through study completion, an average of 1 month</time_frame>
    <description>Duration of hospitalisation in days</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Target Population</arm_group_label>
    <description>Adults with COVID-19 diagnosed and treated with Remdesivir after Aug 31st2020.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir</intervention_name>
    <description>treated with Remdesivir</description>
    <arm_group_label>Target Population</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with COVID-19 diagnosed and treated with Remdesivir after Aug 31st2020.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        All Adult participants with COVID-19 confirmed by PCR who meet the following criteria:&#xD;
&#xD;
          -  Hospitalised after August 31st,2020&#xD;
&#xD;
          -  Receivedat least one dose of Remdesivir(RDV)at anytime during hospitalisation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received Remdesivir as part of a clinical trial, compassionate use or expanded access&#xD;
             program&#xD;
&#xD;
          -  Received Remdesivir prior to this admission at any other health facility than the&#xD;
             research sites and whose health records are available.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anton Pozniak</last_name>
    <phone>00442087465620</phone>
    <email>anton.pozniak@chelwest.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francois Raffi</last_name>
      <email>francois.raffi@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Francois Raffi, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Lariboisiere</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Molina</last_name>
      <email>jean-michel.molina@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michael Molina</last_name>
      <email>jean-michel.molina@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michael Molina, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadir Arber, Dr</last_name>
      <email>narber@tauex.tau.ac.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus Medical Center</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Casper Rokx, Dr</last_name>
      <email>c.rokx@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lourdes Mateu, Dr</last_name>
      <email>lmateu.germanstrias@gencat.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Soriano, Dr</last_name>
      <email>viladomiu@me.com</email>
    </contact>
    <investigator>
      <last_name>Alex Soriano, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Herbon</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrian Curran</last_name>
      <email>acurran@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Adrian Curran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincente Estrada, Dr</last_name>
      <email>vincente.estrada@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Lumbreras, Dr</last_name>
      <email>carlos/lumbreras@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ameet Bakhai, Dr</last_name>
      <email>asbakhai@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Ameet Bakhai, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chelsea &amp; Westminster Hospital</name>
      <address>
        <city>London</city>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pallav Shah, Dr</last_name>
      <email>P.Shah@rbht.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Pallav Shah, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 19, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remdesivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

